Wide Ranks

LPCN

Lipocine Inc.

4.45

Top Statistics
Market Cap 23 M Forward PE -3.59 Revenue Growth 0.00 %
Current Ratio 12.56 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -176.80 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -1.04 Enterprise / Revenue 2.10 Price To Sales Trailing12 Months 4.96
Profitability
Profit Margins -176.80 % Operating Margins -3676.18 %
Balance Sheet
Total Cash 22 M Total Cash Per Share 4.22 Total Debt 245384
Total Debt To Equity 1.16 Current Ratio 12.56 Book Value Per Share 3.83
All Measures
Short Ratio 280.00 % Message Board Id finmb_8057882 Fax 801 994 7388
Shares Short Prior Month 138797 Return On Equity -0.3412 City Salt Lake City
Uuid 137197be-0b23-343c-8f5a-babc45642296 Previous Close 4.42 First Trade Date Epoch Utc 1 B
Book Value 3.83 Beta 1.19 Total Debt 245384
Volume 42783 Price To Book 1.16 Last Split Date 1 B
Fifty Two Week Low 2.38 Total Cash Per Share 4.22 Total Revenue 4 M
Shares Short Previous Month Date 1 B Target Median Price 21.50 Max Age 86400
Sand P52 Week Change 0.3133 Operating Margins -3676.18 % Target Mean Price 21.50
Net Income To Common -8488236 Short Percent Of Float 0.0207 Implied Shares Outstanding 5 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 26820
Average Volume10days 26820 Total Cash 22 M Next Fiscal Year End 1 B
Revenue Per Share 0.9030 Held Percent Insiders 0.0291 Ebitda Margins -201.50 %
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 4.42 Target Low Price 10.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 5.09 Open 4.46 Free Cashflow -4606258
State UT Dividend Yield 0.00 % Return On Assets -0.2267
Time Zone Short Name EST Trailing Eps -0.7500 Day Low 4.45
Address1 675 Arapeen Drive Shares Outstanding 5 M Price Hint 4
Target High Price 33.00 Website https://www.lipocine.com 52 Week Change 0.8465
Average Volume 31443 Forward Eps -1.24 Recommendation Key none
Compensation As Of Epoch Date 1 B Quick Ratio 1239.80 % Last Split Factor 1:17
Regular Market Day High 4.78 Is_sp_500 False Profit Margins -176.80 %
Debt To Equity 1.16 Fifty Two Week High 11.79 Day High 4.78
Shares Short 107537 Regular Market Open 4.46 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 2.10 Revenue Growth 0.00 %
Shares Percent Shares Out 0.0201 Operating Cashflow -4718595 Currency USD
Time Zone Full Name America/New_York Market Cap 23 M Is_nasdaq_100 False
Zip 84108 Quote Type EQUITY Industry Biotechnology
Long Name Lipocine Inc. Regular Market Day Low 4.45 Held Percent Institutions 0.0996
Current Price 4.45 Address2 Suite 202 Enterprise To Ebitda -1.04
Financial Currency USD Current Ratio 12.56 Gross Margins 100.00 %
Industry Disp Biotechnology Number Of Analyst Opinions 2 Country United States
Float Shares 5 M Two Hundred Day Average 5.30 Enterprise Value 10 M
Price To Sales Trailing12 Months 4.96 Forward PE -3.59 Regular Market Volume 42783
Ebitda -9673982 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders.

Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.

The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor.

It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth.

The company was founded in 1997 and is headquartered in Salt Lake City, Utah.